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Message from Mark Coticchia, M.S. 
Vice President for Innovation, Baptist Health Innovations 
B aptist Health Innovations is pleased to partner with Dr. Lipkin, as the Corporate Vice President for Research, in 
supporting Baptist Health’s journey toward the top echelon of 
health system innovators. 
Innovation is more than a buzzword.  It is a driver of patient, 
physician and other professionals’ satisfaction and is a well-
recognized metric in evaluating an Institution’s status.  It is no 
coincidence that institutions which are recognized as the top 
healthcare institutions are also viewed as preeminent innovators.  
See the below chart.   
At Baptist Health, we are on the journey.  On May 1, 2020, we 
adopted our first Intellectual Property Policy.  Establishing clear 
ownership of Intellectual Property (IP) is the building block in any 
successful commercialization program and Baptist adopted a 
sharing program with its contributors, which is as generous as 
any that the Baptist Health Innovations is familiar with. One-half 
of Net Proceeds from licensing, after expenses and charges, 
is shared with the creators of new IP, as described in more 
precise detail in the BHSF Intellectual Property Policy. 
In addition, of the remaining 50%, 20% is directed toward the 
needs of the business unit where the creators generated the 
intellectual property. 
Since adoption of that Policy, Baptist Health Innovations has 
negotiated a number of major licensing deals which have their 
genesis in past and future research.  In this issue, take a look at 
some of these projects as well as other innovative strategies 
used in clinical research. 




it is done.” 
~Robert Heinlein~ 
Immediate Correlation among hospital rankings and 
perceived innovation capacity 
Newsweek 2021 Best 
Hospitals 
Becker’s 8 Most Innovative 
Hospitals 
1. Mayo Clinic Mayo Clinic (#1) 
2. Cleveland Clinic Cleveland Clinic (#2) 
3. Mass General Mass General (#7) 
4. Johns Hopkins Johns Hopkins (#4) 
Quote: Between Planets (1951), Chapter 2 
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COTA is a healthcare technology firm founded in 2011 by 
oncologists, engineers, and data scientists, with the goal of 
transforming cancer care so that treatment is benefited 
by relevant prior data. 
Baptist Health Innovations first negotiated a noteworthy 
license to COTA for cancer treatment data and a separate 
license for intellectual property generated by Dr. Leonard 
Kalman, the Executive Deputy Director and Chief Medical 
Officer at the Miami Cancer Institute (MCI), with regard to 
the means of analyzing treatment information for improved outcomes.  Both licenses are 
royalty bearing. 
Subsequently, as part of Baptist Health Innovation’s mission to diversify Baptist Health’s 
revenue streams, Baptist Health Innovations co-led a Series D round capital investment 
in COTA. Dr. Kalman joined the board of COTA as part of the investment round.  
Baptist Health Innovations will continue to strengthen its collaboration with COTA as the 
company uses real-world data to improve outcomes in cancer care and oncology drug 
development.  
 
Cleerly is a healthcare company with a mission to create 
a new standard of care for coronary artery disease 
to help prevent the millions of heart attacks that occur 
worldwide ever year. The company aims to create 
innovative strategies toward the prevention of heart 
attacks, including the application of artificial intelligence and analytics.  
Cleerly has executed a royalty bearing license to utilize Baptist Health’s deidentified data on 
cardiovascular disease, which will lead to the construction of an analytical tool, aimed at 
benchmarking the degree of a patient’s cardiac disease against others who have had 
coronary disease treatment. The tool will benefit greatly from the Miami Heart Study data 
gathered by Baptist Health.  Dr. Jonathan Fialkow and others are working to present 
that data in the most useful form.   
 
Stem Cell Provider 
Earlier this year, a Master Sponsored Research and 
License Agreement was entered with a globally-
recognized source of stem cells for clinical research 
by Dr. Guenther Koehne, Deputy Director, MCI.   
While there is still much to be done and the efficacy as a 
therapeutic treatment still must be established, we are 
excited by the potential of this market. Only three years 
ago, the global cell therapy market was estimated at $2 
billion. By 2025, it is expected to exceed $8 billion.  
 
Electron micrograph of stem cells, color-enhanced for clarity.  Photo from FDA. 
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For many years Baptist Health has had a relationship with Philips, 
principally through Miami Cardiac & Vascular Institute (MCVI), which 
has been beneficial to both parties in various ways.  However, that 
relationship had not previously provided an avenue for direct 
participation by BHSF and its employee creators of IP in the proceeds of 
Philips’ commercialization of said IP generated at BHSF.  Part of the 
reason for this had been the absence of an IP Policy at BHSF.  With the 
staffing of Baptist Health Innovations and the enactment of a system-
wide IP Policy, BHSF has both the legal capability of holding title to and 
licensing the IP created by its employees AND the personnel able to devote the time 
needed to develop the commercial potential of the IP assets of Baptist Health. 
At the encouragement and with the considerable assistance of Dr. Barry Katzen, MCVI Chief 
Medical Executive, and Carol Melvin, MCVI Chief Operating Officer, Innovations undertook 
the mission of formalizing, expanding to the entire system, and harmonizing with our new IP 
Policy the research and development relationship with Philips.  An initial Memorandum of 
Understanding (MOU) was executed with Philips, effective March 12, 2020, and the parties 
commenced negotiations in earnest, which produced  the Master Research Collaboration 
Agreement, signed April 2, 2021. We anticipate multiple research and development projects 
under this Agreement, potentially involving all operational units of Baptist Health. 
 
With Dr. Scott Lipkin’s and my signatures, 
and Dr. Michael Chuong’s (Radiation 
Oncologist, MCI) assistance, BHSF has entered a new Master Research and License 
Agreement with ViewRay, under which BHSF clinicians will have a broader opportunity to 
share in monetization of the fruits of their research. 
In addition, the Master Research and License Agreement enables collaborative projects to 
be developed under appropriate statements of work, which should be signed by both Dr. 
Lipkin and me to assure that both the research and the IP aspects are covered consistently 
with this new Master Research and License Agreement.    
 
Baptist Health Innovations has completed a collaboration and license 
agreement with QurHealth Solutions, Inc. (a spinout of Ventech 
Solutions).  The collaboration centers around IP developed at MCI called 
the NAVCISE Call Center Algorithm (patent pending, know how, trade 
secrets) which was developed by Matthew Baumann, MBA, MCI’s 
Assistant Vice President of Operations.  Matt applied his knowledge of 
patient experience strategy in developing the NAVCISE algorithm.   
NAVCISE incorporates patient language identification to route calls.   
Baptist Health Innovations is funding, through the generous philanthropic support of a donor, 
the creation of a prototype for NAVCISE and combining the expertise and resources of both 
Baptist and QurHealth in the technology and healthcare space.  QurHealth will work with 
MCI to develop a minimal viable product or a proof of concept that will be tested and 
integrated into the MCI call center.  At that point, the call center can be integrated into 
Salesforce and physician conversations can be integrated into the electronic health record. 
QurHealth will have a license to implement and license the NAVCISE technology to other 
institutions in the US and abroad.   
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All of these transactions emanate from the highly valuable, world-class research that our 
clinicians and other professionals are performing.  Baptist Health Innovations, along 
with Dr. Lipkin and the General Counsel’s Office, seeks to find homes for the valuable 
intellectual property that our clinicians and other professionals generate.  And that is the true 
spirit of what we are attempting to do, i.e., taking the results of our research and clinical 
development efforts out into practice both inside and outside the walls of Baptist 
Health while at the same time sharing in the fruits of the commercialization of such 
intellectual property with our commercial licensees and collaborators.  But you, who generate 
the intellectual property, are the wellspring of Innovation.  Keep it coming. 
—Mark Coticchia, M.S., Vice President for Innovation, Baptist Health Innovations 
INTRODUCTION 
DR. QAMMER BOKHARI, VP AND CHIEF CLINICAL TRANSFORMATION AND MEDICAL INFORMATICS OFFICER 
T o piggyback off the discussion of innovation at Baptist Heath, we are excited to introduce you to another executive who is 
leading the charge in innovation through informatics and analytics.  
Qammer Bokhari, MD, MBA, MHSA, CPHIMS is a seasoned 
physician executive, IT strategist, medical informaticist, and 
population heath specialist who recently joined Baptist Health in May 
as Corporate Vice President and Chief Clinical Transformation & 
Medical Informatics Officer.  
Dr. Bokhari came to us from a large and high-performing multi-state 
health system, Advent Health, where he served as Corporate Vice 
President and Chief Medical Informatics Officer.  There, he was 
responsible for planning, organization, and coordination of the EHR digital technology 
implementation, “Big Data” analytics governance and strategy, decision support integration, 
medical operations support, patient safety, quality improvement, population health, and 
evidence- and practice-based medical innovations using six sigma and lean methodologies.  
At Baptist Health, Dr. Bokhari will focus on clinical systems functionality, enhancing clinical 
outcomes and efficiency, and the clinician-patient experience. He will play a lead role in 
driving improved functionality supporting medical and clinical activities, enabled by applying 
technology and digital systems. He will spearhead the use of analytics and informatics to 
improve clinical efficiency and outcomes across the care continuum.   He also will support 
research at BHSF via the services offered by the Center for Advanced Analytics.  He 
has hit the ground running and is currently getting to know the people and teams at Baptist 
Health, understanding our company culture and building the clinical transformation roadmap. 
Dr. Bokhari completed his medical and surgical training at Rawalpindi Medical College at the 
University of Punjab, Pakistan, and obtained a Master of Business Administration (MBA) at 
Preston University in Pakistan and a Master of Health Services Administration (MHSA) at 
The George Washington University in Washington, DC.   
—Don Parris, Ph.D., Assistant Vice President, Center for Advanced Analytics 
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T he fast-paced nature of the competitive pharmaceutical industry and the public 
pressure to make medical advances rapidly 
available (e.g., COVID-19) have forced clinical 
trial designers to re-think the simplified approach 
of testing a single drug for a single disease.  
Collectively known as Master Protocol designs – 
basket, umbrella and platform study designs are 
being used to help expedite the drug testing 
process.  These are designed either to let 
multiple different drugs get an attempt to treat a 
single disease (umbrella design) or use a single 
drug to catch multiple different types/sub-sets of a 
condition (basket design).  In combination, 
platform designs do both and test multiple drugs 
against multiple conditions at various starting/
stopping points.  Overall, these innovative, new 
designs minimize the cost (both money and 
resources) it takes to test multiple drugs that 
otherwise would be needed for multiple clinical 
trials while also helping to bring opportunities to 
difficult to recruit or treat populations (e.g., rare diseases or cancers with very specific 
mutation types).  
 
Reference: J Woodcock and M LaVange. Master Protocols to Study Multiple Therapies, Multiple Diseases, or 
Both. N Engl J Med 2017; 377:62-70. DOI: 10.1056/NEJMra1510062 
The New Masters of Design 
UMBRELLAS, BASKETS AND PLATFORMS  
Article and images by Nicholas Chow, Pharm.D., BCOP, Clinical Pharmacy Supervisor, Miami Cancer Institute 
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T he Neuro-Oncology team at Boca Raton Regional Hospital (BRRH) comprises a multidisciplinary team of physicians, 
including medical and radiation oncology, neurosurgery, 
neuroradiology and neuropathology. Research administration 
provides support to conduct clinical trials. The Neuro-Oncology 
research program is part of the Marcus Neuroscience Institute 
(MNI) and Lynn Cancer Institute (LCI) and is led by Sajeel 
Chowdhary, M.D.  The dedicated research nurse, Veronica 
Kerr, RN and the research coordinator, Maria Pilar Zuniga work 
closely with the physician team to enroll patients in studies.  
The clinical trial portfolio include trials for primary brain tumor 
and brain metastasis.  Two trials are open for enrollment for 
those with newly diagnosed glioblastoma: 
TRIDENT EF-32: “Randomized, open label study of Optune (TT 
Fields, 200 KHz) concomitant with radiation therapy and TMZ”   
 Use of the Optune device [tumor treating (TT fields)] which delivers low intensity (1-3 
V/cm), intermediate frequency (200 KHz), alternating electric fields to the tumor using 
non-invasive transducer arrays placed on the skin, in this case the scalp 
 Optune Device >18 hr/d for maximal effectiveness 
 Patients are randomized to use this device concomitant to radiation therapy and 
temozolomide (TMZ)  vs. to use the device during adjuvant TMZ 
DENOVO DB102-01: “A randomized, double blind, placebo controlled Phase 3 Study of 
enzastaurin added to temozolomide during and following radiation therapy in newly 
diagnosed GBM patients who possess the novel genomic biomarker DGM1” 
 Patients are randomized to receive enzastaurin vs. placebo concomitant to standard 
care (radiation therapy & TMZ) 
Our neuro-oncology program also offers clinical trials for brain metastasis:  
 A071701: Genomically guided treatment trial in brain metastasis 
 CE.7: Stereotactic radiosurgery (SRS) compared with hippocampal avoidant whole 
brain radiotherapy plus memantine for 5-15 brain metastases 
 A071801: Single fraction SRS compared with fractionated SRS for resected 
metastatic brain disease 
Patients with glioblastoma face many challenges, such as impairments in cognition, social 
skills, and emotional wellbeing. Our research team works closely with patients and their 
families to support them throughout the trial and they often establish long lasting relations 
beyond the duration of their participation in the trial.  
—Maria Pilar Zuniga, Clinical Research Coordinator, and Viviana Boronat, M.D., MBA, 
Director of Research, Boca Raton Regional Hospital 
SPOTLIGHT ON BOCA 
 
Neuro-Oncology Research at Boca Raton Regional Hospital 


































West Kendall Baptist 
Hospital 
Laura Canino Moreno, 
Pharm.D. 
PGY-1 Resident 





Boca Raton Regional 
Hospital 
New & Transferred Staff Updates 
Md Ashfaq Ahmed, 
Ph.D. 
Biostatistician 
Center for Advanced 
Analytics 
Maliha Alam, MPH 
Clinical Research 
Coordinator 
Office of Clinical 
Research, MCI 
Julie Barrocas, BSN, 
RN 
Clinical Trials Nurse 












Miami Cancer Institute 





















Office of Clinical 
Research, MCI 
Jorge Goyco Diaz 
Research Data 
Coordinator 
Center for Research 
















Antonio Marrero, RN 
Clinical Trials Nurse 
Office of Clinical 
Research, MCI 
















Miami Cancer Institute 
Frank Moreno, 
Pharm.D. 










Clinical Trials Nurse 
Office of Clinical 
Research, MCI 
Raquel Ojeda, RN, 
BSN 
Clinical Data Analyst 













Office of Clinical 
Research, MCI 
Dilanis Perche, M.D. 
Multi-site Oncology 
Coordinator 
Office of Clinical 
Research, MCI 








Clinical Trials Nurse 
Office of Clinical 
Research, MCI 
Toukie Vongprachith 
Supervisor of Protocol 
Activation  
Office of Clinical 
Research, MCI 
Juan Carlos Zevallos, 
M.D. 
Research Fellow 
















South Miami Hospital 






Baptist Hospital of 
Miami 
Zhenwei Zhang, Ph.D. 
Biostatistician 









Office of Clinical 
Research, MCI 
New & Transferred Staff Updates 
11 
Explore some of our recent publications! 
New Article Alcove 
Dmytriw AA, Dibas M, Schirmer CM, Settecase F, Heran MKS, 
Efendizade A...Linfante I, Dabus G et al. (2021) Age and acute 
ischemic stroke outcome in North American patients with COVID-
19.  J Am Heart Assoc 10:e021046.  Find it here! 
Valero-Elizondo J, Chouairi F, Khera R, Granghi GR, Saxena A, et. Al 
(2021) Atherosclerotic cardiovascular disease, cancer, and financial 
toxicity among adults in the United States.  JACC: CardioOncol 3(2): 
236-246.  Find it here! 
Greenwood J, Belnap S, Dabus G, Linfante I, De Los Rios La Rosa F 
(2021) Risk of contracting SARS-CoV-2 (COVID-19) from hospital 
admission and the impact of protection efforts on acute stroke 
treatment .  Clin Neurol Neurosurg 207:106793.  Find it here! 
Kim H, Lee YC, Benedict SH, Dyer B, Price M, Rong Y et al. (2021) Dose summation strategies for 
external beam radiation therapy and brachyther 
achytherapy in gynecologic malignancy: a review from 
the NRG Oncology and NCTN medical physics 
subcommittees.  Int J Radiat Oncol Biol Phys S0360-3016
(21):00737-9.  Find it here! 
Manchanda K, Nakonezy P, Sathy AK, Sanders DT, Starr 
AJ, Wukich DK (2021) A systematic review of ankle 
fracture treatment modalities in diabetic patients.  J Clin 
Orthop Trauma 16:7-15.  Find it here! 
Renshaw A (2021) Updating the Papanicolaou Society 
cytologic criteria for invasive adenocarcinoma in cystic 
pancreaticobiliary specimens.  Cancer Cytopathol 129
(8):579-580. Find it here! 
Sucharew H, Kleindorfer D, Khoury JC, Alwell K, 
Haverbusch M, Stanton R...De Los Rios La Rosa F et al. (in 
press) Deriving place of residence, modified Rankin 
Scale, and EuroQol-5D scores from the medical record 
for stroke survivors.  Cerebrovasc Dis Find it here! 
REMINDER:  Backissues of the Research Matters 
newsletter can be found on the Scholarly Commons in 
addition to all our published research.  Find them here! 
Photo by Henry Be on Unsplash 
Explore more publications from the 
Baptist Health Institutional Repository 
Center for Advanced Analytics 
Center for Research 
Christine E. Lynn Heart & Vascular 
Institute 
Christine E. Lynn Women's Health & 
Wellness Institute 
Eugene M. & Christine E. Lynn Cancer 
Institute 
Marcus Neuroscience Institute 
Miami Cancer Institute 
Miami Cardiac & Vascular Institute 
Miami Neuroscience Institute 
Miami Orthopedics & Sports 
Medicine Institute 
Did we miss your publication?  
Please send it to: library@baptisthealth.net 
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Tuesdays 12:00 to 1:00 pm 
Invite was sent out to Research Operations & 
Regulatory teams. Certificates provided. 
Because of the COVID-19 pandemic, we will be 
doing Zoom™ meetings only until further notice. 
Click here or go to baptisthealth.zoom.us  
Meeting ID: 958 8490 1869 
Password: 861787 
Date Topic 
Tuesday, September 14th Principles of Good Clinical Practice 
Tuesday, October 12th Preventing Noncompliance 
Tuesday, November 9th Participant Recruitment 
Tuesday, December 14th Study Documentation 
by Pharmacy, Nursing & Clinical Research Organizations 
UPCOMING CONFERENCES 
CCP Annual Meeting—September 13-17, 2021, Virtual 
https://accp1.org/Members/Annual_Meeting/ACCP1/3Annual_Meeting/
Letter_of_Invitation.aspx 
SOCRA—September 24-26, 2021, Virtual 
https://www.socra.org/annual-conference/future-annual-conference-dates/  
ACRP Regulatory Trends & Compliance—September 16, 23, 30, 
2021, Virtual 
https://2021.acrpnet.org/regulatory-trends-compliance 
Onsemble Conference—October 5-8, 2021, Virtual  
https://conference.onsemble.net/  
Nursing World Conference—October 18-21, 2021, Virtual 
https//www.magiworld.org/Eventinfo 
MAGI Fall Conference—October 18-28, 2021, Virtual 
https://nursingworldconference.com/  
ANCC Magnet & Pathway—November 11-13, 2021, Atlanta, GA  
https://www.magnetcon.org/ 





To serve as a 
research hub for 
elevating care 
through discovery for 
the diverse 
community we serve 
by using a shared 




collaborative intellect.  
 
VISION 
In alignment with the 
strategic goals of 
Baptist Health South 
Florida, and within the 
context of a 
sustainable business 




knowledge with the 
goals of providing 
continued excellence 
in patient care for the 
diverse multicultural 
community of South 
Florida. 
Research Compliance would like to take the time to thank everyone 
who promptly completed the CCOI form during the 2021 Annual 
Disclosure period! As of the 9th of September, 2021, we are tracking 
a total of 948 research personnel with only 250 personnel (26%) that 
are non-compliant. Our office is working with study teams to get the 
remaining investigators compliant and providing department 
compliant status reports. 
With the expansion of the team, our Research Compliance 
Coordinator (Jacqueline Grass) is conducting the initial compliance 
reviews, in the order they are submitted, via IRBNet. In order to 
conduct these reviews, it is required that Jackie and myself are 
provided “Read-Only” access to all studies and Compliance 
Requests via IRBNet. In addition, we recommend that all Research 
Compliance related communication is sent to our shared inbox,  
ResearchCompliance@baptisthealth.net, to ensure a speedier 
response.  
Stay tuned for upcoming process improvements! 
Do you have any questions or topics you would like 
for us to cover regarding conflicts of interest, 
compliance review, or billing compliance process? 
If so, contact us directly for all Research 
Compliance matters at: 
 ResearchCompliance@baptisthealth.net!  
—Heather Osorio, Research Compliance & Billing 
Administrator   
Research Compliance Corner 
To contribute to this newsletter, please contact Dr. Amy Starosciak at amyst@baptisthealth.net or x79546. 
UPCOMING IRB DATES 
BHSF IRB 
Full Board Committee Meeting: Tuesday, September 28th  
Submission Deadline for October Meeting: Monday, September 27th 
MCI IRB 
Full Board Committee Meeting: Tuesday, September 14th 
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